Candida infections in non-neutropenic children after the neonatal period

Simple item page
dc.contributor.buuauthorHacımustafaoğlu, Mustafa Kemal
dc.contributor.buuauthorÇelebi, Solmaz
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Pediatri ve Pediatri Enfeksiyon Hastalıkları Anabilim Dalı.tr_TR
dc.contributor.scopusid6602154166tr_TR
dc.contributor.scopusid7006095295tr_TR
dc.date.accessioned2022-01-06T11:32:02Z
dc.date.available2022-01-06T11:32:02Z
dc.date.issued2011-10
dc.description.abstractThere are a variety of diseases, from local mucous membrane infections to invasive systemic infections, that are caused by Candida species. As a causative agent, Candida albicans is the most common; however, the other Candida species can also cause the same clinical syndromes. Most invasive fungal infections in children occur in the hospital setting. Candidemia is a serious condition associated with high morbidity and mortality and increased healthcare costs in pediatric patients. Children at the highest risk are those with prolonged intensive care unit stays, reduced immune function, recent surgery, prior bacterial infection, prior use of antibiotics and/or corticosteroids and other immunosuppressive agents, as well as use of a central venous catheter, total parenteral nutrition, mechanical ventilation and dialysis. Positive blood culture is the gold standard of candidemia; it should not be accepted as contamination or colonization in children with an intravascular catheter. However, in oropharyngeal or vulvovaginal candidiasis, culture of lesions is rarely indicated unless the disease is recalcitrant or recurrent. Recovery of Candida from the sputum should usually be considered as colonization and should not be treated with antifungal therapy. Antigen and antibody detecting tests are evaluated in invasive Candida infections; however, there are no published results in children, and their roles in diagnosis are also unclear. For the therapy of invasive Candida infections in non-neutropenic patients, fluconazole or an echinocandin is usually recommended. Alternatively, amphotericin B deoxycholate or lipid formulations of amphotericin B can also be used. The recommended therapy of Candida meningitis is amphotericin B combined with flucytosine. The combination therapy for Candida infections is usually not indicated. Prophylaxis in non-neonatal, immunocompetent children is not recommended.en_US
dc.identifier.citationHacımustafaoğlu, M. ve Çelebi, S. (2011). "Candida infections in non-neutropenic children after the neonatal period". Expert Review of Anti-Infective Therapy, 9(10), 923-940.en_US
dc.identifier.endpage940tr_TR
dc.identifier.issn1478-7210
dc.identifier.issn1744-8336
dc.identifier.issue10tr_TR
dc.identifier.pubmed21973304tr_TR
dc.identifier.scopus2-s2.0-80053630376tr_TR
dc.identifier.startpage923tr_TR
dc.identifier.urihttps://doi.org/10.1586/eri.11.104
dc.identifier.urihttps://www.tandfonline.com/doi/abs/10.1586/eri.11.104
dc.identifier.urihttp://hdl.handle.net/11452/23905
dc.identifier.volume9tr_TR
dc.identifier.wos000297299600018tr_TR
dc.indexed.pubmedPubmeden_US
dc.indexed.scopusScopusen_US
dc.indexed.wosSCIEen_US
dc.language.isoenen_US
dc.publisherTaylor & Francisen_US
dc.relation.journalExpert Review of Anti-Infective Therapyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergitr_TR
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectInfectious diseasesen_US
dc.subjectMicrobiologyen_US
dc.subjectPharmacology & pharmacyen_US
dc.subject.emtreeAmphotericin Ben_US
dc.subject.emtreeAnidulafunginen_US
dc.subject.emtreeAntifungal agenten_US
dc.subject.emtreeButaconazoleen_US
dc.subject.emtreeCaspofunginen_US
dc.subject.emtreeClotrimazoleen_US
dc.subject.emtreeEchinocandinen_US
dc.subject.emtreeFluconazoleen_US
dc.subject.emtreeFlucytosineen_US
dc.subject.emtreeItraconazoleen_US
dc.subject.emtreeKetoconazoleen_US
dc.subject.emtreeMicafunginen_US
dc.subject.emtreeMiconazoleen_US
dc.subject.emtreeNystatinen_US
dc.subject.emtreePyrroleen_US
dc.subject.emtreeTerconazoleen_US
dc.subject.emtreeTioconazoleen_US
dc.subject.emtreeTriazoleen_US
dc.subject.emtreeUnclassified drugen_US
dc.subject.emtreeVoriconazoleen_US
dc.subject.emtreeAntibody detectionen_US
dc.subject.emtreeAntigen detectionen_US
dc.subject.emtreeAsymptomatic infectionen_US
dc.subject.emtreeCandida albicansen_US
dc.subject.emtreeCandidemiaen_US
dc.subject.emtreeCandidiasisen_US
dc.subject.emtreeCandiduriaen_US
dc.subject.emtreeCardiac candidiasisen_US
dc.subject.emtreeCentral nervous system candidiasisen_US
dc.subject.emtreeChilden_US
dc.subject.emtreeChildhood diseaseen_US
dc.subject.emtreeClinical featureen_US
dc.subject.emtreeDrug bioavailabilityen_US
dc.subject.emtreeDrug dosage form comparisonen_US
dc.subject.emtreeDrug dose comparisonen_US
dc.subject.emtreeDrug dose reductionen_US
dc.subject.emtreeEsophagus candidiasisen_US
dc.subject.emtreeFungal colonizationen_US
dc.subject.emtreeFungal detectionen_US
dc.subject.emtreeFungal virulenceen_US
dc.subject.emtreeFungus growthen_US
dc.subject.emtreeFungus transmissionen_US
dc.subject.emtreeGastrointestinal candidiasisen_US
dc.subject.emtreeGram stainingen_US
dc.subject.emtreeHigh risk infanten_US
dc.subject.emtreeHistopathologyen_US
dc.subject.emtreeHumanen_US
dc.subject.emtreeInfection risken_US
dc.subject.emtreeLaboratory testen_US
dc.subject.emtreeLoading drug doseen_US
dc.subject.emtreeMolecular pathologyen_US
dc.subject.emtreeMortalityen_US
dc.subject.emtreeMucocutaneous candidiasisen_US
dc.subject.emtreeMusculoskeletal candidiasisen_US
dc.subject.emtreeMycosisen_US
dc.subject.emtreeNeutropeniaen_US
dc.subject.emtreeNewbornen_US
dc.subject.emtreeNewborn perioden_US
dc.subject.emtreeNonhumanen_US
dc.subject.emtreeOcular candidiasisen_US
dc.subject.emtreeOropharynx candidiasisen_US
dc.subject.emtreePeritoneal candidiasisen_US
dc.subject.emtreePolymerase chain reactionen_US
dc.subject.emtreePrevalenceen_US
dc.subject.emtreePyelonephritisen_US
dc.subject.emtreeRadiodiagnosisen_US
dc.subject.emtreeRespiratory tract candidiasisen_US
dc.subject.emtreeReviewen_US
dc.subject.emtreeRisk assessmenten_US
dc.subject.emtreeRisk factoren_US
dc.subject.emtreeSkin candidiasisen_US
dc.subject.emtreeUrinary tract candidiasisen_US
dc.subject.emtreeVagina candidiasisen_US
dc.subject.meshAmphotericin Ben_US
dc.subject.meshAntifungal agentsen_US
dc.subject.meshCandidaen_US
dc.subject.meshCandidemiaen_US
dc.subject.meshCatheter-related infectionsen_US
dc.subject.meshChilden_US
dc.subject.meshCross infectionen_US
dc.subject.meshDeoxycholic aciden_US
dc.subject.meshDrug combinationsen_US
dc.subject.meshEchinocandinsen_US
dc.subject.meshFluconazoleen_US
dc.subject.meshFlucytosineen_US
dc.subject.meshHumansen_US
dc.subject.meshInfant, newbornen_US
dc.subject.meshIntensive care unitsen_US
dc.subject.meshLeukocyte counten_US
dc.subject.meshMycological typing techniquesen_US
dc.subject.meshNeutrophilsen_US
dc.subject.meshSurvival rateen_US
dc.subject.meshUnited statesen_US
dc.subject.scopusCandidemia; Invasive Candidiasis; Candida Parapsilosisen_US
dc.subject.wosInfectious diseasesen_US
dc.subject.wosMicrobiologyen_US
dc.subject.wosPharmacology & pharmacyen_US
dc.titleCandida infections in non-neutropenic children after the neonatal perioden_US
dc.typeReview
dc.wos.quartileQ1en_US

Files

License bundle
Now showing 1 - 1 of 1
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Web of Science
Scopus